Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zirabev,ZIRABEV2023US,2023,USA,MDV,350,68,42,58,27.5,35,85,12,15,30,40,15,55,25,15,5,20,35,45,18,7,4,9,3,22,48,33,FOLFOX,CAPOX,CAPOX,5-FU/LV,5,3,2,25,60,40,15,45,40,60,2
Zirabev,ZIRABEV2022EU,2022,Germany,Claim Database,420,72,38,62,26.8,40,78,15,12,28,45,15,50,30,15,5,18,32,50,22,9,5,11,4,25,52,35,FOLFOX,XELOX,XELOX,5-FU/FA,6,4,3,30,65,45,10,50,40,70,1
Zirabev,ZIRABEV2024JP,2024,Japan,MDV,280,65,45,55,24.5,28,90,10,18,32,35,15,60,20,15,5,25,40,35,15,6,3,8,2,20,45,30,FOLFOX,mFOLFOX6,mFOLFOX6,CapeOX,4,2,1,20,55,35,20,40,40,55,3
Zirabev,ZIRABEV2023CA,2023,Canada,Claim Database,380,70,40,60,28.0,38,82,13,14,29,42,15,53,27,15,5,19,33,48,20,8,4,10,3,23,50,34,CAPOX,FOLFOX,FOLFOX,CapeOX,5,3,2,28,63,43,12,48,40,65,2
